Amarantus Bioscience (OTCMKTS:AMBS) & GeneDx (NASDAQ:WGS) Head-To-Head Survey

Amarantus Bioscience (OTCMKTS:AMBS) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Institutional and Insider Ownership

61.7% of GeneDx shares are owned by institutional investors. 10.3% of Amarantus Bioscience shares are owned by insiders. Comparatively, 29.6% of GeneDx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Amarantus Bioscience and GeneDx”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarantus Bioscience	N/A	N/A	N/A	N/A	N/A
GeneDx	$427.54 million	4.84	-$21.02 million	($0.75)	-94.25

Amarantus Bioscience has higher earnings, but lower revenue than GeneDx.

Volatility & Risk

Amarantus Bioscience has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, GeneDx has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Amarantus Bioscience and GeneDx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarantus Bioscience	0	0	0	0	0.00
GeneDx	1	0	7	1	2.89

GeneDx has a consensus target price of $150.71, suggesting a potential upside of 113.20%. Given GeneDx’s stronger consensus rating and higher probable upside, analysts plainly believe GeneDx is more favorable than Amarantus Bioscience.

Profitability

This table compares Amarantus Bioscience and GeneDx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarantus Bioscience	N/A	N/A	N/A
GeneDx	-4.92%	14.73%	8.67%

Summary

GeneDx beats Amarantus Bioscience on 10 of the 11 factors compared between the two stocks.

About Amarantus Bioscience

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.